ASP546C / Evopoint, Astellas - LARVOL DELTA

XNW27011: “Preliminary efficacy in CLDN18.2+ G/GEJ adenocarcinoma”; Gastric cancer or gastroesophageal junction adenocarcinoma (Astellas) - Q1 FY2025 Results

P1/2 data • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology

Efficacy and safety of XNW27011, a Claudin 18.2 targeting antibody drug conjugate with topoisomerase 1 inhibitor payload, in patients with Claudin 18.2 positive gastric/gastroesophageal junction cancer: Results from ongoing phase I/II study. (ASCO 2025) - P1/2 | "In the expansion cohorts, XNW27011 demonstrated promising anti-tumor activity and favorable safety profile in GC/GEJC pts with wide expression level of CLDN18.2. The results support further development of XNW27011 in CLDN18.2+ GC/GEJC."

Clinical • P1/2 data • Anemia • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases • Solid Tumor • CLDN18

Astellas Enters Exclusive License Agreement with Evopoint Biosciences for XNW27011, a Novel Clinical-stage Antibody-Drug Conjugate Targeting CLDN18.2 (Astellas Press Release) - "The agreement grants Astellas a worldwide (excluding China's mainland, Hong Kong, Macao and Taiwan region) exclusive license to develop and commercialize XNW27011...Under the terms of the agreement, Evopoint will receive a $130 million upfront payment and is eligible to receive up to $70 million near-term payments, and additional milestone payments associated with development, regulatory and commercialization milestones totaling up to $1.34 billion, as well as royalties on net sales of XNW27011, if approved."

Licensing / partnership • Gastric Cancer • Gastroesophageal Cancer • Pancreatic Cancer

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. (clinicaltrials.gov) - P1/2 | N=240 | Recruiting | Sponsor: Evopoint Biosciences Inc.

New P1/2 trial • Biliary Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors (ESMO 2024) - "Prior PD-1 immunotherapy, irinotecan or CLDN18.2 antibody therapy seemed not to impact efficacy. XNW27011 demonstrated a favorable safety profile with large therapeutic window, superior preliminary efficacy across tumor type and CLDN 18.2 expression level, and excellent PK properties including low payload plasma exposure. The study is ongoing with the expansion phase being initiated in multiple tumor cohorts."

Clinical • IO biomarker • Metastases • P1 data • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor • CLDN18